BioRestorative’s BRTX-100 Phase 3 Design Endorsed by FDA with Safety Data
BioRestorative won FDA endorsement for its Phase 3 design of BRTX-100 after a Type B meeting, with 99-patient Phase 2 safety endpoints raising no clinical concerns. FDA endorsed dosing, outcome measures, sample size and CMC alignment, prompting launch of Phase 3 IND enabling activities for submission later this year.
1. FDA Meeting Outcome
BioRestorative completed a Type B meeting with the FDA on its Fast-Track-designated BRTX-100 program for chronic lumbar disc disease, discussing positive clinical safety endpoints from the ongoing 99-patient Phase 2 trial. The FDA raised no clinical safety concerns, validating the therapy’s favorable safety profile.
2. Phase 3 Design Endorsement
The FDA endorsed the proposed Phase 3 trial design, including outcome assessments, dosing strategy, eligibility criteria, sample size and powering assumptions. Feedback confirmed alignment of ongoing Chemistry, Manufacturing and Controls activities ahead of the investigational new drug application.
3. Next Steps
Following the positive official meeting summary, BioRestorative has initiated Phase 3 enabling activities and plans to submit the Phase 3 IND application in the second half of 2026. This endorsement supports an expedited Biologics License Application pathway for BRTX-100.